Alembic Pharmaceuticals experienced a significant boost in its stock value following an announcement that the U.S. Food and Drug Administration (USFDA) had issued an Establishment Inspection Report (EIR). This report confirmed the successful closure of an inspection at the company's Bioequivalence Facility located in Vadodara, Gujarat, prompting a nearly 4% rise in share price during Wednesday's trading.
USFDA Inspection Concluded
The USFDA conducted its inspection of Alembic Pharmaceuticals' Bioequivalence Facility in Vadodara from March 3 to March 7, 2025. The vertically integrated Indian pharmaceutical firm had previously informed stock exchanges about the completion of this inspection.
According to an exchange filing dated September 16, 2026, the USFDA has now formally issued the EIR, signaling the closure of the inspection process. The company, however, did not disclose specific details or any observations contained within the EIR.
Stock Performance Overview
Following the positive regulatory news, Alembic Pharmaceuticals' shares opened at Rs 834.70, up from their previous close of Rs 824.40. The stock reached an intraday high of Rs 855.60, ultimately trading up by 3.78% from its prior closing price. This upward movement reflects investor confidence in the company after receiving the crucial USFDA clearance for its Vadodara facility.